Literature DB >> 10653212

Comparison of central and peripheral pharmacologic effects of biperiden and trihexyphenidyl in human volunteers.

S K Guthrie1, L Manzey, D Scott, B Giordani, R Tandon.   

Abstract

In this double-blind, randomized study, indices of central (memory, sedation) and peripheral (salivation, ratio of R-R interval on electrocardiogram) muscarinic function were evaluated in 14 healthy volunteers who received trihexyphenidyl, biperiden, and placebo. Additionally, serum drug levels were obtained 2 hours after oral administration. All subjects participated in three study sessions. During each session, subjects received two doses of biperiden (4 mg), trihexyphenidyl (5 mg), or placebo, and four series of tests were administered. The tests included the determination of cardiac response to standing (R-R ratio), mouth salivation, finger-tapping speed, digit span (forward and backward), a selective reminding task, and visual analog scales (VAS). On the VAS, subjects rated biperiden as significantly more sedating than either trihexyphenidyl or placebo, and both biperiden and trihexyphenidyl were associated with more dizziness than was placebo. Saliva production was significantly reduced by both trihexyphenidyl and biperiden compared with placebo. Digit span performance was significantly decreased in only the backward direction. The selective reminding task revealed highly significant decrements in the number of words recalled and consistent long-term retrieval after both biperiden and trihexyphenidyl. Delayed recall was significantly decreased by both active drugs. Both trihexyphenidyl and biperiden caused a significant increase in the R-R ratio comparison with placebo. With the exception of the VAS measurement of sedation, the effects caused by biperiden and trihexyphenidyl did not differ. The results of this study do not support the hypothesis that the side effect profile of biperiden is significantly different from that of trihexyphenidyl.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10653212     DOI: 10.1097/00004714-200002000-00013

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  8 in total

1.  Modulation of memory and visuospatial processes by biperiden and rivastigmine in elderly healthy subjects.

Authors:  E Wezenberg; R J Verkes; B G C Sabbe; G S F Ruigt; W Hulstijn
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

Review 2.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia.

Authors:  Anthony M Downs; Xueliang Fan; Christine Donsante; H A Jinnah; Ellen J Hess
Journal:  Neurobiol Dis       Date:  2019-01-30       Impact factor: 5.996

Review 4.  Pharmacological management of anticholinergic delirium - theory, evidence and practice.

Authors:  Andrew H Dawson; Nicholas A Buckley
Journal:  Br J Clin Pharmacol       Date:  2015-12-29       Impact factor: 4.335

5.  Human electrophysiological correlates of learned irrelevance: effects of the muscarinic M1 antagonist biperiden.

Authors:  Inge Klinkenberg; Arjan Blokland; Wim Riedel; Anke Sambeth
Journal:  Int J Neuropsychopharmacol       Date:  2011-11-18       Impact factor: 5.176

6.  Hippocampus and basal forebrain volumes modulate effects of anticholinergic treatment on delayed recall in healthy older adults.

Authors:  Stefan J Teipel; Davide Bruno; Michel J Grothe; Jay Nierenberg; Nunzio Pomara
Journal:  Alzheimers Dement (Amst)       Date:  2015-05-07

7.  Why an M1 Antagonist Could Be a More Selective Model for Memory Impairment than Scopolamine.

Authors:  Arjan Blokland; Anke Sambeth; Jos Prickaerts; Wim J Riedel
Journal:  Front Neurol       Date:  2016-09-30       Impact factor: 4.003

8.  Biperiden Challenge Model in Healthy Elderly as Proof-of-Pharmacology Tool: A Randomized, Placebo-Controlled Trial.

Authors:  Charlotte Bakker; Michiel J van Esdonk; Rik F E Stuurman; Laura G J M Borghans; Marieke L de Kam; Joop M A van Gerven; Geert Jan Groeneveld
Journal:  J Clin Pharmacol       Date:  2021-07-29       Impact factor: 3.126

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.